Alzex Neuropharma Inc. (TRRI)
OTCMKTS · Delayed Price · Currency is USD
0.0005
+0.0002 (66.67%)
At close: Apr 10, 2026
Alzex Neuropharma Revenue
In the year 2011, Alzex Neuropharma had annual revenue of $4.73M with 23.83% growth. Alzex Neuropharma had revenue of $916.10K in the quarter ending June 30, 2011, with 23.58% growth.
Revenue
4.73M
Revenue Growth
+6.73%
P/S Ratio
0.00
Revenue / Employee
430.37K
Employees
11
Market Cap
753.00
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2011 | 4.73M | 911.14K | 23.83% |
| Dec 31, 2010 | 3.82M | -4.98M | -56.58% |
| Dec 31, 2009 | 8.80M | -6.18M | -41.24% |
| Dec 31, 2008 | 14.98M | -142.18K | -0.94% |
| Dec 31, 2007 | 15.13M | 868.37K | 6.09% |
| Dec 31, 2006 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| DNAPrint Genomics | 1.93M |
| Biora Therapeutics | 892.00K |
| Trevena | 546.00K |
| RegeneRx Biopharmaceuticals | 76.76K |
| Proteonomix | 26.00K |
Alzex Neuropharma News
- 3 years ago - Trinity Resources Inc. Awaiting Regulatory Approval of Name and Symbol Change - Newsfile Corp
- 4 years ago - Trinity Resources Inc. Finalizes the Purchase of Alzex Biomedical Assets and Intellectual Property - Newsfile Corp